Alcaptonuria
A genetic disorder causing homogentisic acid buildup, resulting in dark urine when exposed to air, blue-black connective tissue pigmentation (ochronosis), and early severe arthritis.
Emergency Management: Management of acute complications like nephrolithiasis causing acute urinary obstruction, or severe symptoms from aortic stenosis.
Alcaptonuria is a rare autosomal recessive metabolic disorder caused by a deficiency in homogentisate 1,2-dioxygenase (HGD). This deficiency leads to the accumulation of homogentisic acid (HGA) in connective tissues, cartilages, and the skin. The hallmark of the disease is the darkening of urine upon exposure to air and early-onset severe osteoarthritis.
Detailed Overview
The accumulation of HGA produces a dark pigment called ochronotic pigment, which deposits in various tissues (ochronosis). Over time, this causes significant structural damage, particularly in load-bearing joints like the spine, knees, and hips, leading to disabling osteoarthritis in early adulthood. It also deposits in heart valves, causing valvular calcification and stenosis.
Epidemiology & Demographics
Extremely rare, affecting 1 in 250,000 to 1 in 1,000,000 live births globally. Higher prevalence in specific populations like Slovakia and the Dominican Republic. Occurs equally in males and females.
Etiological Mechanism
Mutations in the HGD gene located on chromosome 3q13.33, resulting in defective homogentisate 1,2-dioxygenase enzyme.
Primary Causes
Inheritance of two mutated copies of the HGD gene (autosomal recessive inheritance).
Normally, homogentisic acid is broken down into maleylacetoacetic acid. HGD deficiency halts this pathway. Excess HGA is excreted in urine, but a significant amount oxidizes into benzoquinone acetic acid (BQA). BQA forms melanin-like polymers that bind covalently to collagen and other structural proteins in connective tissues, rendering them brittle, prone to micro-tears, and triggering chronic inflammation and structural failure.
Diagnostic Criteria & Guidelines
Diagnosis is confirmed by detecting significantly elevated levels of HGA in the urine using gas chromatography-mass spectrometry (GC-MS) (typically 1 to 8 grams per day, whereas normal is trace). Genetic testing for biallelic mutations in the HGD gene confirms the specific defect.
Nitisinone 2 mg orally once daily. Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), the enzyme that produces HGA, drastically reducing HGA levels (up to 95%). Dietary protein restriction (tyrosine and phenylalanine) is required concurrently to prevent corneal toxicity from tyrosinemia.
Second-Line & Adjunctive Therapy
High-dose Vitamin C (ascorbic acid) up to 1 gram daily was historically used to reduce HGA oxidation into BQA, though it does not prevent joint destruction or lower HGA levels significantly. Pain management with NSAIDs (e.g., Naproxen 500 mg BID).
Surgical & Procedural Management
Total joint arthroplasty (knee, hip, or shoulder) for end-stage ochronotic arthropathy. Aortic or mitral valve replacement for severe valvular calcification/stenosis.
Patient Counseling & Advice
Explain the progressive nature of the joint disease and the critical importance of adhering to the restricted diet when taking nitisinone to prevent eye complications. Genetic counseling should be offered to family members.
Follow-Up & Monitoring Schedule
Annual comprehensive evaluation including physical exam, urine HGA levels, plasma tyrosine levels (if on nitisinone), echocardiogram (every 1-2 years after age 40), and eye exam (to monitor for corneal crystals if on nitisinone).
Preventive Strategies
As an inherited genetic disorder, it cannot be prevented. Genetic counseling and prenatal testing are available for at-risk families.
Life expectancy is usually normal, but morbidity is high due to severe early-onset osteoarthritis and chronic pain, significantly impacting quality of life.